Suchergebnisse - "Langer, Jakob"

PubPharm (101)

31

Quality of Life and Utility Values for Cost-Effectiveness Modeling in Japanese Patients with Type 2 Diabetes

enthalten in: Diabetes therapy | 2020

von Ishii, H. | Takamura, H. | Nishioka, Y. | +4

32

Quality of Life and Utility Values for Cost-Effectiveness Modeling in Japanese Patients with Type 2 Diabetes

enthalten in: Diabetes therapy | 2020

von Ishii, H. | Takamura, H. | Nishioka, Y. | +4

33

Quality of Life and Utility Values for Cost-Effectiveness Modeling in Japanese Patients with Type 2 Diabetes

enthalten in: Diabetes therapy | 2020

von Ishii, H. | Takamura, H. | Nishioka, Y. | +4

34

Response to "Letter to the Editor Regarding : Patient Preferences for Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment"

enthalten in: Diabetes therapy : research, treatment and education of diabetes and related disorders | 2020

von Brooks, A. | Langer, J. | Tervonen, T. | +3

35

Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan : A Short-Term Cost-Effectiveness Analysis

enthalten in: Advances in therapy | 2020

von Igarashi, A. | Hunt, B. | Wilkinson, L. | +2

36

Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis

enthalten in: Advances in therapy | 2020

von Igarashi, A. | Hunt, B. | Wilkinson, L. | +2

37

Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis

enthalten in: Advances in therapy | 2020

von Igarashi, A. | Hunt, B. | Wilkinson, L. | +2

38

Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis

enthalten in: Advances in therapy | 2020

von Igarashi, A. | Hunt, B. | Wilkinson, L. | +2

39

Response to “Letter to the Editor Regarding: Patient Preferences for Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment”

enthalten in: Diabetes therapy | 2020

von Brooks, A. | Langer, J. | Tervonen, T. | +3

40

Response to “Letter to the Editor Regarding: Patient Preferences for Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment”

enthalten in: Diabetes therapy | 2020

von Brooks, A. | Langer, J. | Tervonen, T. | +3